Details werden geladen...
Ultragenyx Q3 Loss Narrows; Reaffirms 2027 Profit Outlook | 03.11.26 | finanzen.ch
(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on developing therapies for serious rare and ultra-rare gen...
Ähnliche Seiten
Shoulder Innovations Q3 Loss Narrows, Lifts FY26 Revenue Outlook | 05.11.26 | finanzen.ch
https://www.finanzen.ch/nachrichten/aktien/shoulder-innovations-q3-loss-narrows-lifts-fy26-revenue-outlook-1036725967Materialise Q3 Profit Declines; Reaffirms FY26 Adj. EBIT, Revenue Outlook | 28.10.26 | finanzen.ch
https://www.finanzen.ch/nachrichten/aktien/materialise-q3-profit-declines;-reaffirms-fy26-adj-ebit-revenue-outlook-1036676056Kimberly-Clark Q3 Profit Surges; Reaffirms FY26 Outlook | 05.11.26 | finanzen.ch
https://www.finanzen.ch/nachrichten/aktien/kimberly-clark-q3-profit-surges;-reaffirms-fy26-outlook-1036722458Medline Q3 Profit Falls, Reaffirms FY26 Adj. EBITDA Outlook; Shares Up | 04.11.26 | finanzen.ch
https://www.finanzen.ch/nachrichten/aktien/medline-q3-profit-falls-reaffirms-fy26-adj-ebitda-outlook;-shares-up-1036714689
Shoulder Innovations Q3 Loss Narrows, Lifts FY26 Revenue Outlook | 05.11.26 | finanzen.at
https://www.finanzen.at/nachrichten/aktien/shoulder-innovations-q3-loss-narrows-lifts-fy26-revenue-outlook-1036725967